NCT07336875 is a EARLY_PHASE1 clinical trial of CAR-ITNK Cells targeting CD70 and CLL1 in R/R AML, sponsored by Tongji Hospital.

Who is sponsoring NCT07336875?

NCT07336875 is sponsored by Tongji Hospital.

What drugs are being tested in NCT07336875?

Interventions in NCT07336875: CAR-ITNK Cells targeting CD70 and CLL1.

Is NCT07336875 still recruiting?

NCT07336875 is currently not yet recruiting. Last updated 13 January 2026.

Last reviewed 2026-01-13 · How we verify

NCT07336875

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML

Not yet recruiting EARLY_PHASE1 Last updated 13 January 2026

What this trial tests

EARLY_PHASE1 trial testing CAR-ITNK Cells targeting CD70 and CLL1 in R/R AML in 30 participants. Not yet recruiting.

Timeline

28 February 2026

Primary endpoint
28 February 2028

28 February 2029

Quick facts

Lead sponsor	Tongji Hospital
Phase	EARLY_PHASE1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	28 February 2026
Primary completion	28 February 2028
Estimated completion	28 February 2029

Drugs / interventions tested

CAR-ITNK Cells targeting CD70 and CLL1 — full drug profile →

Conditions studied

R/R AML — all drugs for R/R AML →

Sponsor

Tongji Hospital

Who can join

Adults 18 to 75, any sex, with R/R AML. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to evaluate the safety and efficacy of CAR-ITNK cells therapy targeting CD70 and CLL1 in participants with relapsed/refractory Acute Myeloid Leukemia. Participants will receive a single infusion of CAR-ITNK cell therapy targeting CD70 and CLL1 and complete follow-ups over the next three years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for R/R AML

Currently open trials in the same condition.

NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting

Other Tongji Hospital trials

Trials by the same sponsor.

NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07336875 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
Last refreshed: 13 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07336875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing